ArticleHuman mutation2026
Decoding the Sphingolipid Landscape of Clear Cell Renal Cell Carcinoma: A Single-Cell-Guided Prognostic Model Built With 101 Machine Learning.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer and shows marked heterogeneity in progression, metastasis, and therapeutic response. Sphingolipid metabolism has emerged as an important regulator of tumor progression and the tumor microenvironment, but its cell-state-specific role in ccRCC remains unclear. Methods: Public datasets from multiple cohorts were integrated, including single-cell RNA sequencing data from GEO and bulk transcriptomic and clinical data from Xena, ArrayExpress, and ICGC. Nonnegative matrix factorization was used to resolve cellular heterogeneity and identify sphingolipid metabolism-related characteristic genes across distinct cell subsets. A prognostic model was constructed by screening 101 machine learning combinations and validated in independent cohorts. Additional analyses included immune characterization, pathway enrichment, drug sensitivity prediction, protein-protein interaction network analysis, and mutation profiling. Results: Single-cell analysis identified 23 cell clusters representing nine major cell types in ccRCC and further resolved multiple sphingolipid metabolism-related metagene-defined subclusters within immune and stromal compartments. Based on these features, 101 machine learning combinations were evaluated, and a final 12-gene prognostic signature was established using the Lasso+SuperPC model. The model showed stable prognostic performance across independent cohorts and outperformed conventional clinical variables. It was also associated with distinct immune features, predicted therapeutic vulnerabilities, and mutation-related genomic characteristics. Conclusion: This study provides a single-cell-guided framework for understanding sphingolipid metabolism-related heterogeneity in the ccRCC microenvironment and establishes a 12-gene prognostic signature with potential value for risk stratification and therapeutic prioritization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.